Who makes Dual antithrombotic therapy with NOAC and clopidogrel?

Dual antithrombotic therapy with NOAC and clopidogrel is developed by Yonsei University.

What development phase is Dual antithrombotic therapy with NOAC and clopidogrel in?

Dual antithrombotic therapy with NOAC and clopidogrel is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Dual antithrombotic therapy with NOAC and clopidogrel

Yonsei University · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Dual antithrombotic therapy with NOAC and clopidogrel
Sponsor	Yonsei University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents (PHASE4)
Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage (NA)
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dual antithrombotic therapy with NOAC and clopidogrel CI brief — competitive landscape report
Dual antithrombotic therapy with NOAC and clopidogrel updates RSS · CI watch RSS
Yonsei University portfolio CI